Despite azithromycin being used in some countries to treat infections caused by Gram-negative pathogens, no resistance breakpoint for Escherichia coli exists. The aim of this study was to analyse the levels and mechanisms of azithromycin resistance in E. coli. The presence of chromosomal (rplD, rplV and 23S rRNA) mutations, 10 macrolide resistance genes (MRGs) and efflux pump overexpression was determined in 343 E. coli isolates. Overall, 89 (25.9%) isolates had MICs\xE2\x80\x89\xE2\x89\xA5\xE2\x80\x8932\xE2\x80\x89mg/L to azithromycin, decreasing to 42 (12.2%) when assayed in the presence of Phe-Arg-\xCE\xB2-Napthylamide, with 35 of these 42 possessing at least one MRG. Efflux pumps played a role in azithromycin resistance affecting the Minimal Inhibitory Concentration (MIC) levels of 91.2% isolates whereas chromosomal alterations seem to have a minimal role. At least one MRG was found in 22.7% of the isolates with mph(A) being the most commonly found gene. The mph(A) gene plays the main role in the development of azithromycin resistance and 93% of the mph(A)-carrying isolates showed a MIC of 32\xE2\x80\x89mg/L. In the absence of a specific resistance breakpoint our results suggest a MIC of 32\xE2\x80\x89mg/L to be considered in order to detect isolates carrying mechanisms able to confer azithromycin resistance.